Venture Capital Panelist Presentation Slides - Chbmr.com

Recommendations

Info

Our track record Current Portfolio Sales and IPOs: • Cita: sold to Vernalis in 2005 • Kadmus: sold to Organon in 2007 • Targanta: IPO on NASDAQ in 2007/ sold to The Medicines Company 2008 • VSI: Sold to Sonosite in June 2010 Financings, partnerships, acquisition offers • Aegera: >$300M deal with Human Genome Sciences • Axela/Xceed: Deal with Kimberley-Clark and Gen-Probe • Cytochroma: Deal with Mitsubishi Tanabe Pharmaceutical Corp • TTI: Deals with Medarex/BMS, Genentech and Biogen-Idec • Interface Biologics: Multiple deals with large medtech Coes; Fresenius • Zelos: US$45M Financing round led by Alta Partners (Frazier, Prospect, SROne) Confidential and Proprietary 34
VG Partners: Our Value-Add VisualSonics Inc. - Device At Time of First Investment • Pre-commercial company with ultrasound imaging product • Animal imaging with potential to expand into human applications Accomplishments • Acted as lead investor for all financing rounds • Recruited executives including CFO from our network • Recruited Board members and industry experts • Funded development of 2nd generation device with clinical utility • Oversaw VSI to $30M in revenues and world class product commercialization Outlook • Current Cash Position: EBITDA Positive • Sold to Sonosite: June-2010 Confidential and Proprietary 35
Page 1 and 2: Christine Sarkisian Trade Commissio
Page 3 and 4: The New England Economy • Thrives
Page 5 and 6: The Consulate’s Priority Sectors
Page 7 and 8: Virtual Trade Commissioner Powerful
Page 9 and 10: Opportunities • Agriculture, Food
Page 11 and 12: Opportunities • Ocean Technologie
Page 13 and 14: Life Sciences Connections • 500 b
Page 15 and 16: Our Team Consul General Pat Binns M
Page 17 and 18: Dr. Peter Farina Canaan Partners
Page 19 and 20: OVERVIEW About Canaan Partners » 2
Page 21 and 22: Areas of Interest » Biologics & Sm
Page 23 and 24: Typical Investment » Phase I or Ph
Page 25 and 26: Canaan Investment Model » Canaan u
Page 27 and 28: Dr. Luc Marengère VenGrowth Partne
Page 29 and 30: VG Partners Life Sciences Team Team
Page 31 and 32: VG Partners Life Sciences Team Four
Page 33: Our track record - Capital Leverage
Page 37 and 38: Creating Sustainable Value Luc Mare
Page 39 and 40: Synergy Partners International Syne
Page 41 and 42: Synergy Interests Cancer Therapy an
Page 43 and 44: Representative Portfolio Companies
Page 45 and 46: TVM Capital Life Sciences Practice
Page 47 and 48: TVM Capital life science profile
Page 49 and 50: Creating substantial companies Sour
Page 51 and 52: Long-term stability paired with gro
Page 53 and 54: Projected Growth of Large Pharmaceu
Page 55 and 56: Two Emerging Strategies In Life Sci
Page 57 and 58: Tom Hayes GrowthWorks Atlantic Ltd
Page 59 and 60: GrowthWorks Overview � GrowthWork
Page 61 and 62: Retail venture capital (RVC) � Ra
Page 63 and 64: Contributions from Provincial Treas
Page 65 and 66: GWA Portfolio Companies Company Sec
Page 67 and 68: Dr. Christian Cortis Advanced Techn
Page 69 and 70: 69 ATV OVERVIEW � Now in its 30 t
Page 71 and 72: 71 Characteristics of Compelling In
Page 73 and 74: 73 Recent Life Science Investments
Page 75 and 76: Hercules Technology Growth Capital
Page 77 and 78: HTGC Life Science Underwriting Guid
Page 79 and 80: 79 Life Sciences Portfolio at a Gla

Venture Capital Panelist Presentation Slides - Chbmr.com

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?